Gain-of-function mutations in the calcium ion-sensing receptor (CaR) cause hypocalcemia with low PTH levels. It is stated that patients with activating CaR mutations generally show milder degree of hypocalcemia before treatment and more profound hypercalciuria during treatment than those with idiopathic hypoparathyroidism (IHP). To test this validity we analyzed the data of serum and urinary calcium collected from 85 patients with IHP and 15 with activating CaR mutations. The mean (ϮSEM) serum calcium concentration before treatment was significantly higher (P Ͻ 0.001) in patients with activating CaR mutations (1.76 Ϯ 0.05 mmol/L; n ϭ 15) than in those with IHP (1.41 Ϯ 0.03; n ϭ 58), but there was a substantial overlap in the range of hypocalcemia between the two groups (1.25-2.05 vs. 0.90 -1.95). The mean urinary calcium/creatinine ratio (Ca/Cr) in patients with activating CaR mutations before treatment (0.362 Ϯ 0.045 mmol/mmol; n ϭ 9) was almost equal to that in normocalcemic controls (0.331 Ϯ 0.022; n ϭ 56) and markedly higher (P Ͻ 0.001) than in patients with IHP (0.093 Ϯ 0.008; n ϭ 57). The overlap of pretreatment urinary Ca/Cr between the 2 disorders was relatively small; subnormal urinary Ca/Cr was observed in only 1 of 9 patients with CaR mutations and in the majority (49 of 57) of patients with IHP. In contrast to pretreatment findings, the degree of hypercalciuria during treatment was not different between the 2 disorders. The data points of urinary Ca/Cr plotted as a function of the serum calcium concentration were not separable between patients with CaR mutations (n ϭ 8) and those with IHP (n ϭ 40). Comparison of urinary Ca/Cr between 2 patients with a CaR mutation and 7 with IHP over a wide range of serum calcium concentrations measured during 4 -8 yr of treatment also indicated that the 2 disorders were inseparable. These results suggested that inappropriately normal urinary Ca/Cr in patients with untreated hypocalcemia, mostly of mild degree, might be a better biochemical clue than the development of severe hypercalciuria during treatment to suspect gain-of-function mutations in the CaR. (J Clin Endocrinol Metab 85: [4583][4584][4585][4586][4587][4588][4589][4590][4591] 2000) 
in patients with IHP (0.093 Ϯ 0.008; n ϭ 57). The overlap of pretreatment urinary Ca/Cr between the 2 disorders was relatively small; subnormal urinary Ca/Cr was observed in only 1 of 9 patients with CaR mutations and in the majority (49 of 57) of patients with IHP. In contrast to pretreatment findings, the degree of hypercalciuria during treatment was not different between the 2 disorders. The data points of urinary Ca/Cr plotted as a function of the serum calcium concentration were not separable between patients with CaR mutations (n ϭ 8) and those with IHP (n ϭ 40). Comparison of urinary Ca/Cr between 2 patients with a CaR mutation and 7 with IHP over a wide range of serum calcium concentrations measured during 4 -8 yr of treatment also indicated that the 2 disorders were inseparable. These results suggested that inappropriately normal urinary Ca/Cr in patients with untreated hypocalcemia, mostly of mild degree, might be a better biochemical clue than the development of severe hypercalciuria during treatment to suspect gain-of-function mutations in the CaR. (J Clin Endocrinol Metab 85: 4583-4591, 2000) P TH-DEFICIENT hypoparathyroidism of unknown etiology has historically been called idiopathic hypoparathyroidism (IHP). IHP consists of a heterogeneous group of sporadic and familial hypoparathyroidism, from which new clinical entities with identified causes, such as abnormalities in the PTH gene (1, 2) , are being separated. Recent cloning and characterization of the gene encoding the extracellular calcium ion-sensing receptor (CaR) revealed another genetic cause for hypoparathyroidism (3, 4) . It was found that binding of calcium ion to the CaR on parathyroid cells decreases PTH secretion, and thus the CaR determines the set-point of PTH secretion by acting as a calcium sensor. In accordance with this concept, patients with gain-of-function mutations in the CaR exhibit hypocalcemia, hyperphosphatemia, and detectable, but inappropriately low, levels of immunoreactive PTH (5) (6) (7) (8) (9) (10) (11) (12) . These biochemical findings are, however, not unique to patients with mutations in the CaR, but are common to patients with so-called IHP (13) .
It is reported that vitamin D therapy in patients with activating CaR mutations often results in a disproportionate hypercalciuria and may increase the risk of nephrocalcinosis, nephrolithiasis, and eventually renal insufficiency (7) (8) (9) . If the risk of hypercalciuria and resultant complications during treatment is higher in patients with CaR mutations than in those with other types of PTH-deficient hypoparathyroidism, detection of such patients would be of great clinical importance. At present, the only way to diagnose patients with CaR mutations accurately is molecular genetic studies. However, it would be too laborious and time-consuming to examine the CaR gene thoroughly in all patients with hypoparathyroidism and conduct functional analysis of the abnormal gene when a novel mutation is found. Therefore, from both scientific and practical viewpoints, it is a focus of interest whether we can distinguish patients with CaR mutations from those with so-called IHP before undertaking molecular studies, in other words, whether there is a way to select patients who are candidates for examination of probable CaR mutations.
One characteristic that may help identify patients with CaR mutations is familial occurrence as an autosomal dominant hypoparathyroidism (5-7). However, documentation of sporadic forms of CaR mutations (8, 10) made the family history less useful. Another characteristic associated with CaR mutations is the earlier onset of hypocalcemia. Presentation in infancy or early childhood strongly suggests genetic disorders, but there are patients with hypoparathyroidism due to abnormalities in genes other than CaR (1, 2). Furthermore, some patients with CaR mutations may present in adulthood (8, 12) . If clinical characteristics alone are not sufficient to suspect CaR mutations in patients with hypoparathyroidism, additional means of potential usefulness must be sought. As biochemical characteristics, it is stated that hypocalcemia before treatment is milder and hypercalciuria during treatment is more profound in patients with activating CaR mutations than in those with other forms of PTH-deficient hypoparathyroidism (7) (8) (9) . In relation to hypercalciuria it is shown that the CaR is expressed in the kidney, most notably in the thick ascending limb of Henle (14, 15) , and activation of the CaR inhibits calcium reabsorption. It is assumed, therefore, that correction of hypocalcemia may result in hypercalciuria of greater magnitude in patients with activating CaR mutations than in those with simple PTH deficiency. However, as hypercalciuria is a common finding in patients with any form of PTH-deficient hypoparathyroidism treated with vitamin D analogs with or without calcium supplements (16 -18) , it remains to be established that hypercalciuria during treatment is actually more profound in patients with activating CaR mutations than in those with IHP.
In this study we analyzed the data of 85 patients with so-called IHP and 15 patients with proven activating mutations in the CaR to address the following: 1) whether there were significant differences between groups with CaR mutations and IHP in serum calcium concentrations and urinary calcium excretion either before or during treatment, and if so, based on these data 2) whether we could discriminate a subgroup of patients who might have CaR mutations from the rest of population with IHP.
Subjects and Methods Subjects
There were 4 groups of patients. Group I comprised 73 patients with so-called IHP (37 males and 36 females, aged 13-71 yr), whose data were obtained from a previous nationwide collaborative study of a PTH infusion test (19) . They satisfied the following criteria: 1) documentation of hypocalcemia, hyperphosphatemia, and undetectable or inappropriately low levels of serum immunoreactive PTH; 2) no history of thyroidectomy or parathyroidectomy; 3) serum creatinine or blood urea nitrogen concentrations within normal range; 4) at least 1 measurement of urinary calcium/creatinine ratio (Ca/Cr) either before or during treatment; and 5) age of 11 yr or older at the time of examination. The last criterion was added to exclude data of infants and small children from the analyses because it was reported that normal range of urinary Ca/Cr varied depending on age (20) . Group II comprised 12 patients with IHP (6 males and 6 females, aged 25-73 yr at the start of examination) treated by ourselves (Table 1 ). Of them, 1 patient (no. 10) had a niece with hypoparathyroidism. The others had no family history of hypoparathyroidism. Group III comprised 6 patients (2 males and 4 females, aged 11-75 yr) from the same kindred in which we recently identified a novel activating mutation (S820F) in the CaR (21) . Group IV comprised 9 patients with various CaR mutations, whose data derived from 2 previous studies (7, 12) . Criteria for selecting them were essentially the same as those in group I: age older than 11 yr (ranging from 17-68) and availability of urinary Ca/Cr data either before or during treatment.
Analyses
Comparison of pretreatment serum calcium concentration and urinary Ca/Cr between patients with IHP and CaR mutations. Serum and urinary data were compared among all 4 groups and between IHP (groups I and II) and CaR mutations (groups III and IV). In addition, to confirm that the small number of patients with CaR mutations studied here was a representative population, we analyzed all of the pretreatment serum calcium data of patients with activating CaR mutations (5-9, 11, 12, 22) regardless of the age or availability of urinary Ca/Cr. In this analysis, to avoid unequal influence by the size of each kindred on the results, we calculated the mean value of a kindred when it had multiple affected members. When serum calcium concentrations were given as ranges, the midpoints were used for calculation. s-Ca, Serum total calcium (to convert to mg/dL, multiply by 4.0); s-Pi, serum inorganic phosphorus (to convert to mg/dL, multiply by 3.1); s-Mg, serum magnesium (to convert to mg/dL, multiply by 2.4); u-Ca/Cr, ratio of calcium to creatinine in urine (to convert to mg/mg, multiply by 0.354); u-Ca, 24-h urinary calcium; NA, not available.
Comparison of urinary
IV (5 before and 6 during treatment). Urinary Ca/Cr was plotted as a function of the serum calcium concentration reported concurrently, and the scattergram was compared between groups with IHP and CaR mutations. Patients in group II who had multiple data points were not included because their data were analyzed in-depth as described below.
Comparison of the magnitude of hypercalciuria during treatment between two patients with an activating CaR mutation and seven with IHP. Two patients with an activating CaR mutation in group III (43-yr-old mother and 15-yr-old son at the start of examination) had been treated as IHP before their CaR mutation was identified. From them, random urine and simultaneous blood samples were obtained at 1-to 3-month intervals for 4 yr during treatment with 1␣-hydroxyvitamin D 3 (1␣-OHD 3 ). Their data were compared with those of 7 patients with IHP in group II (no. 6 -12 in Table 1 ) treated similarly for 4 -8 yr. All of the data thus collected were pooled for each patient, and the mean urinary Ca/Cr was calculated at each level of serum calcium, in 0.25 mmol/L increments.
Between-person variation in hypercalciuria during treatment among patients with IHP.
At the beginning of 1␣-OHD 3 therapy, 24-h urine specimens were collected two or three times a week for 2-5 weeks from seven hospitalized patients (no. 1-7 in Table 1 ). Their daily calcium excretion was expressed as the Ca/Cr ratio instead of millimoles per day to correct for the difference in body size among patients and was plotted as a function of fasting serum calcium concentrations measured on the same day. During out-patient therapy, the magnitude of hypercalciuria was evaluated occasionally in 24-h urine samples together with sodium excretion. The renal handling of calcium was assessed in each patient as follows. Casual urine and serum samples were obtained from seven patients (no. 6 -12 in Table 1 ) at each clinical visit. The urinary Ca/Cr was plotted against the serum calcium concentration, and a regression line correlating the two variables was drawn. The apparent renal calcium threshold, which was defined as the serum calcium concentration at which level urine calcium was zero, was determined as an intercept of the regression line on the abscissa. The tubular maximum reabsorption rate of calcium/glomerular filtration rate (TmCa/GFR) was also determined by calculating urinary calcium per 100 mL glomerular filtrate instead of the Ca/Cr ratio (23) .
Measurements and statistics
The data obtained from a previous collaborative study (19) or from the literature (7, 12) were analyzed as they were reported, without detailed information about the assay methods. To express the urinary Ca/Cr ratio in millimoles per mmol, results given in milligrams per mg were recalculated by multiplying by 2.828. In patients studied by ourselves, serum levels of calcium, phosphate, magnesium, and creatinine and urinary concentrations of calcium, sodium, and creatinine were measured using standard laboratory techniques. To define hypercalciuria, spot urine samples were collected from 56 normocalcemic subjects taking no drugs known to alter renal handling of calcium. Their range of Ca/Cr ratios was 0.076 -0.656 mmol/mmol (0.027Ϫ0.232 mg/mg), and the mean Ϯ sd was 0.331 Ϯ 0.170. Based on these data, overt hypercalciuria was defined as a urinary Ca/Cr ratio exceeding 0.700 mmol/mmol (ϳ0.250 mg/mg) and the normal reference range as 0.160Ϫ0.500.
Results are presented as the mean Ϯ sem unless otherwise stated. Statistical analyses were performed using the statistical package StatView (Abacus Concepts, Inc., Berkeley, CA) on a Macintosh computer (Apple Computer, Inc., Tokyo, Japan). Differences between group means were tested by one-way ANOVA and Scheffe's F test. P Ͻ 0.05 at a 95% confidence level was considered significant.
Results

Comparison of pretreatment serum calcium concentration and urinary calcium excretion between patients with IHP and those with activating CaR mutations
The mean serum calcium concentration before treatment was not different between groups I and II with IHP [1.44 Ϯ 0.03 mmol/L (n ϭ 47) vs. 1.27 Ϯ 0.07 (n ϭ 11)] and between groups III and IV with CaR mutations [1.79 Ϯ 0.04 (n ϭ 6) vs.
1.75 Ϯ 0.08 (n ϭ 9)]. When the data were combined for each disorder, the mean serum calcium concentration was significantly (P Ͻ 0.001) lower in patients with IHP (1.41 Ϯ 0.03; n ϭ 58) than in those with CaR mutations (1.76 Ϯ 0.05; n ϭ 15). As shown in Fig. 1 , the range of hypocalcemia overlapped substantially between IHP and CaR mutation groups (0.90 -1.95 vs. 1.25-2.05), but severe hypocalcemia was rare in the latter. A serum calcium concentration below 1.5 mmol/L was observed in only 1 of 15 patients (7%) with CaR mutations vs. 39 of 58 (67%) with IHP. The findings were essentially the same when the serum calcium concentrations obtained from all published cases (13 kindreds including 51 patients) were used as the CaR mutation group (mean, 1.71 Ϯ 0.07 mmol/L; range, 1.20 -2.08).
The mean urinary Ca/Cr ratio before treatment was not different between groups I and II with IHP [0.093 Ϯ 0.010 mmol/mmol (n ϭ 47) vs. 0.094 Ϯ 0.013 (n ϭ 10)] and between groups III and IV with CaR mutations [0.396 Ϯ 0.068 (n ϭ 4) vs. 0.334 Ϯ 0.062 (n ϭ 5)]. The mean of all patients with CaR mutations (0.362 Ϯ 0.045; n ϭ 9) was comparable to that of normocalcemic controls (0.331 Ϯ 0.023; n ϭ 56) and was significantly (P Ͻ 0.001) higher than that of patients with IHP (0.093 Ϯ 0.009; n ϭ 57). Unlike serum calcium concentrations, the overlap of the urinary Ca/Cr ratio between the 2 disorders was relatively small (Fig. 2) . The majority of patients with CaR mutations (8 of 9 ϭ 89%) showed the urinary Ca/Cr ratios within or above the reference range, whereas only 14% (8 of 57) of patients with IHP had values within the lower half of the reference range.
FIG. 1. Comparison of pretreatment hypocalcemia between patients
with idiopathic hypoparathyroidism (IHP) and those with activating CaR mutations. Each symbol represents the serum calcium concentration of one patient, and a horizontal line represents the mean of each group. There are four groups of patients whose data were collected from different sources: group I, IHP from a previous collaborative study; group II, IHP diagnosed and treated by us; group III, a kindred with an activating CaR mutation examined by us; and IV, published cases with activating CaR mutations.
Comparison of urinary calcium as a function of serum calcium concentration between patients with IHP and those with activating CaR mutations
Before treatment (Fig. 3A) , there was a significant positive linear correlation between serum calcium concentration and urinary Ca/Cr ratio in patients with IHP (n ϭ 47; r ϭ 0.57; P Ͻ 0.001), consistent with the renal physiology that urinary calcium increases as the elevation of serum calcium. There was no positive correlation but, rather, a tendency to a negative correlation between the two variables in patients with activating CaR mutations (n ϭ 9; r ϭ Ϫ0.59; P ϭ 0.095). Urinary Ca/Cr values were generally higher in patients with CaR mutations than in those with IHP when compared at similar serum calcium levels although the two groups were not completely separable.
During treatment, under conditions where the mean serum calcium concentrations were still in the hypocalcemic range (1.84 Ϯ 0.04 mmol/L in IHP; 1.98 Ϯ 0.04 in CaR mutations), urinary Ca/Cr was within or above the reference range in 70% (28 of 40) of patients with IHP and in all the patients with CaR mutations. In the latter group, 2 patients studied by ourselves showed the lowest urinary Ca/Cr values (Fig. 3B) . Overt hypercalciuria was more common in the group of CaR mutations (4 of 8 ϭ 50%) than was IHP (5 of 40 ϭ 12.5%), although the total number was small. During treatment (Fig. 3B) and also when the data from before and during treatment were combined (Fig. 3C) , there was a highly significant (P Ͻ 0.001) correlation between serum calcium concentration and urinary Ca/Cr in patients with IHP (n ϭ 40; r ϭ 0.58 and n ϭ 87; r ϭ 0.67). Under both conditions, no correlation was observed in the CaR mutation group (n ϭ 8; r ϭ 0.28; P ϭ 0.495, and n ϭ 17; r ϭ 0.24; P ϭ 0.364). As a whole, the individual data points in a scattergram were not separable between the two groups.
Comparison of the magnitude of hypercalciuria during treatment between seven patients with IHP and two patients with an activating CaR mutation
As shown by individual lines representing the relationships between serum calcium concentrations and urinary Ca/Cr (Fig. 4) , there were considerable between-person variations among seven patients with IHP. Overt hypercalciuria was observed in three patients at subnormal serum calcium concentrations approximately 2.0 mmol/L, whereas three others did not show hypercalciuria at normal serum calcium levels. The lines of two patients with the same CaR mutation were different in position and slope. However, both were located within the variation of patients with IHP. Although overt hypercalciuria was not observed in either of them, the slope of the line suggested that one of them would develop severe hypercalciuria when serum calcium levels were raised slightly higher.
Between-person variation in the development of hypercalciuria after the start of 1␣-OHD 3 therapy in patients with IHP
After the start of 1␣-OHD 3 therapy, 24-h urinary calcium excretion increased progressively with the elevation of fasting serum calcium concentrations. Urinary calcium exceeded the level of overt hypercalciuria in six of seven patients before they attained normocalcemia (Fig. 5) . As long as their serum calcium levels were below 2.0 mmol/L, supplemental calcium did not seem to enhance the magnitude of hypercalciuria. Earlier appearance of hypercalciuria (patients 1, 4, 5, and 2 in that order) was not related to the severity of hypocalcemia before treatment (patients 6, 7, 4, and 1 in that order), although the only patient who did not show hypercalciuria during treatment (no. 3) had the highest pretreatment serum calcium concentration.
Between-person variation in the renal calcium handling among patients with IHP
When urinary Ca/Cr was plotted as a function of the serum calcium concentration determined simultaneously during 4 -8 yr of treatment, there was a significant (P Ͻ 0.05 to P Ͻ 0.001) linear correlation between the two variables in all patients. Reflecting the between-person variation in the position and the slope of regression lines, the intercepts of the lines on the abscissa ranged from 1.24 -1.94 mmol/L (Fig. 6) . Similar between-person variation was observed in the renal calcium threshold calculated as the TmCa/GFR (Table 2) . In general, a lower renal calcium threshold was associated with more profound hypercalciuria and a lesser calcium-raising effect by 1␣-OHD 3 therapy (Table 2 ). Patients 8, 9, and 10, who had the lowest three TmCa/GFR values, remained hypocalcemic during maintenance therapy and satisfied the widely accepted criteria of hypercalciuria (calcium excretion of Ͼ6.25 mmol/day for women, 7.50 mmol/day for men, and 0.1 mmol/kg⅐day for both). The amount of calcium excretion did not correlate with sodium excretion measured on the same day. 
Discussion
The mean serum calcium concentration before treatment was significantly higher in patients with activating CaR mutations than in those with IHP. This observation supports the idea that patients with CaR mutations generally manifest mild hypocalcemia. However, the range of serum calcium concentrations overlapped substantially between the two groups. This is not surprising because it is reported that patients with IHP show a wide range of hypocalcemia (24) . In addition, hypocalcemia of patients with CaR mutations might range from mild to severe grade if the site of gene abnormality in the CaR would determine the severity of hypoparathyroidism, as suggested by Watanabe et al. (11) . It seemed difficult therefore to define a criterial level of hypocalcemia to discriminate the two disorders. In contrast, there was little overlap in the range of pretreatment urinary Ca/Cr between the two groups, suggesting that the urinary Ca/Cr ratio could be a more useful biochemical parameter than the serum calcium concentration to differentiate the two disorders.
Interestingly, the mean urinary Ca/Cr ratio of patients with CaR mutations without treatment was not only higher than that of patients with IHP but also was comparable to the value in normocalcemic controls. This observation has several implications. First, it indicates that patients with CaR mutations are characterized by inappropriately normal calcium excretion under pretreatment hypocalcemic conditions (relative hypercalciuria), but not by absolute hypercalciuria. Second, urinary Ca/Cr in the normal range, especially in its upper half, could be used as a clue to suspect CaR mutations in untreated hypoparathyroid patients because such a situation was extremely rare for patients with IHP. Third, a normal amount of urinary calcium in patients with CaR mutations may imply that their intestinal calcium absorption is also normal. It is well established that calcium excretion in urine approximates its net absorption from the intestine in the steady state and that calcium excretion is affected largely by vitamin D action (25) . Unfortunately, however, we could not find previous literature on the metabolism and action of vitamin D in patients with CaR mutations, except for a few studies reporting baseline serum 1,25-dihydroxyvitamin D concentrations (12, 21) .
The difference in urinary Ca/Cr between the two disorders could result from the difference in serum calcium concentrations and/or renal calcium reabsorption. By comparing urinary Ca/Cr as a function of serum calcium I; OE and , activating CaR mutations from groups III and IV, respectively. The correlation between the serum calcium concentration and urinary Ca/Cr was r ϭ 0.57; P Ͻ 0.001 in IHP group (n ϭ 47) and r ϭ Ϫ0.59; P ϭ 0.095 in the CaR mutation group (n ϭ 9). B, During treatment: E, IHP from group I; OE and , activating CaR mutations from groups III and IV, respectively. The correlation between the serum calcium concentration and urinary Ca/Cr was r ϭ 0.58; P Ͻ 0.001 in the IHP group (n ϭ 40) and r ϭ 0.28; P ϭ 0.495 in the CaR mutation group (n ϭ 8). C, Combined data of before and during treatment: ⌬ and E, patients with IHP before and during treatment, respectively; OE and F, patients with CaR mutations before and during treatment, respectively. The correlation between the serum calcium concentration and urinary Ca/Cr was r ϭ 0.67; P Ͻ 0.001 in the IHP group (n ϭ 87) and r ϭ 0.24; P ϭ 0.364 in the CaR mutation group (n ϭ 17).
concentration, we found that the higher pretreatment urinary Ca/Cr in patients with CaR mutations was not attributable to their milder hypocalcemia compared to those with IHP. Furthermore, we found that the correlation of urinary Ca/Cr to serum calcium concentration was quite different between the two disorders. As expected, patients with IHP exhibited a significant positive linear correlation. In contrast, those with CaR mutations exhibited a tendency to negative correlation. This may be a coincidental finding due to the small number of patients with CaR mutations. An alternative, more tempting interpretation is as follows. If patients with more severe defects in the function of CaR showed lower serum calcium concentrations in association with more urinary calcium loss than those with milder defects, there would be a tendency to a negative correlation rather than a positive one between serum and urinary calcium. In accordance with this concept, Nagano et al. reported a negative correlation between serum concentration and fractional excretion of calcium in a rat model of CaR activation elaborated by infusing a calcimimetic (26) .
Previous studies suggested that hypercalciuria was more common in patients with CaR mutations than in those with IHP or other types of hypoparathyroidism during treatment (7, 8) . In our study the percentage of patients with overt hypercalciuria was greater in the former than in the latter. However, we had a reservation about concluding that hypercalciuria developed more frequently in patients with CaR mutations. It was unclear whether the urinary data of patients with CaR mutations reported in the literature (7) were the mean of multiple measurements or the one-point data, and in case of the latter, whether they were chosen arbitrarily or selected as representative values for the disorder that was theoretically linked with hypercalciuria. The urinary Ca/Cr values of our two patients, which were the lowest and the second lowest in the group of CaR mutations, were the onepoint data determined after 1 month of treatment. Thus, we could not completely rule out the possibility that the published data had some bias toward hypercalciuria. As for the severity of hypercalciuria during treatment, our results did not demonstrate a significant difference between groups with CaR mutations and IHP. The scattergram of urinary Ca/Cr plotted against serum calcium concentration was not separable between the two groups. This finding in the collective study for a relatively large number of patients, but with only one set of data per person, was confirmed by an in-depth study of a limited number of patients with multiple data points.
The seemingly discrepant results between our study and others could be explained by a difference in the age of patients. We excluded patients under 11 yr from the analyses. On the other hand, Pearce et al. (7) documented the most severe hypercalciuria (urinary Ca/Cr, 2.29 mmol/mmol) in a child aged 4 yr. When their patients with CaR mutations were subdivided into two different age groups to match our study, from 11 yr up and below 11 yr, the mean urinary Ca/Cr in the older group (0.76; n ϭ 6) was not so high as in the younger one (1.22; n ϭ 7). It is known that urinary Ca/Cr values in normal children change with age (20) and are distinctly higher in infants below 18 months of age than in older children (27) . Thus, the age of the patient should be taken into consideration when interpreting the results of different studies conducted without age-matched comparison of urinary calcium data between groups with CaR mutations and others. Table  1 ) with IHP. Fasting serum and 24-h urine samples were obtained serially at 2-to 4-day intervals for 2-5 weeks after the start of 1␣-OHD 3 therapy without (solid lines) or with (broken lines) calcium supplements (0.5-1.0 g/day). Daily calcium excretion was expressed as Ca/Cr and plotted as a function of the serum calcium concentration measured on the same day. Overt hypercalciuria was defined as a urinary Ca/Cr higher than 0.70 mmol/mmol (horizontal dotted line), approximating 250 mg/g.
Another difference between our study and some others was the method of how hypercalciuria was evaluated. Baron et al. (8) noticed significantly greater daily calcium excretion in 4 patients with CaR mutations compared with 10 patients with either postsurgical or autoimmune hypoparathyroidism at serum calcium concentrations of approximately 2.0 mmol/L. Mancilla et al. (9) reported hypercalciuria greater than 8.1 mmol/day in patients with an activating CaR mutation at serum calcium concentrations ranging from 2.0 -2.4 mmol/L, but their data were not compared with other types of hypoparathyroidism. These patients were treated with vitamin D analogs and supplemental calcium. On the other hand, we analyzed urinary Ca/Cr mostly in spot samples, over a wide range of serum calcium concentrations. Our patients with an activating CaR mutation were treated with 1␣-OHD 3 alone without calcium supplementation. It is possible, therefore, that hypercalciuria evaluated in 24-h urine was more profound in patients with CaR mutations than in those with other types of hypoparathyroidism when they were taking supplemental calcium and their serum calcium concentrations were near normal. Under such conditions, daily calcium excretion would be affected largely by postprandial increases in calcium absorption. However, there is no evidence that postprandial increases in calcium absorption or in the filtered load of calcium differ between patients with CaR mutations and those with IHP. It is also unknown whether the influence of calcium supplementation is different between the two disorders. Our study in patients with IHP showed that hypercalciuria in 24-h urine became prominent when their fasting serum calcium concentrations exceeded 2.0 mmol/L during treatment with 1␣-OHD 3 and supplemental calcium.
The results of this study do not necessarily contradict the theoretical view that patients with CaR mutations have abnormality in the function of renal tubular CaR, and therefore they are more prone to hypercalciuria. Several explanations are possible for the observation that the magnitude of hypercalciuria during treatment was not different between the groups with CaR mutations and IHP. Studies in the rat have shown that the distribution of the CaR overlaps with that of PTH receptors along the distal nephron (15, 28) . Assuming that renal calcium reabsorption is regulated by the interaction between the two receptor systems and the function of the CaR is influenced by PTH action, a potential difference in calcium reabsorption between the two disorders might be masked during treatment when PTH secretion was suppressed. To disclose the intrinsic difference, it would be necessary to compare the two disorders under conditions where PTH effects are present equally, such as during infusion of exogenous PTH. Another interpretation is that a wide individual variation within each group might have masked certain differences in the calcium excretion between the groups. It has long been recognized that patients with PTH-deficient hypoparathyroidism develop hypercalciuria of various degrees during treatment (16 -18) . Their hypercalciuria is considered inevitable to some extent because vitamin D analogs do not substitute for PTH action to stimulate renal calcium reabsorption (18, 29) . However, the mechanisms for the betweenperson variation in the magnitude of hypercalciuria have not been well defined. Findings in our patients with IHP did not support that the severity of pretreatment hypocalcemia or differences in the treatment regimen determined the degree of hypercalciuria in individual patients. Furthermore, we found considerable between-person variations in the renal calcium handling in two patients with the same CaR mutation treated in the same way. These observations indicate that calcium excretion is variable in individual patients, as reported in normocalcemic subjects with or without hypercalciuria (30) . The underlying mechanisms for the individual variation are unknown, but cannot be explained by differences in PTH effects or the function of CaR.
Lastly, we could not completely rule out the following possibilities. First, some of the patients classified as IHP might have mutations in the CaR. Although we did not conduct genetic analyses, this is unlikely at least for the patients we studied. All of our patients diagnosed as IHP had symptomatic severe hypocalcemia and very low urinary calcium excretion before treatment, characteristics typical of IHP. Second, some patients with IHP might have abnormalities in yet to be identified CaR-related genes, as hypothesized in patients with autosomal dominant hypoparathyroidism who had no detectable mutations in the CaR (5, 7). If so, it would be a natural consequence that we could not differentiate the two groups based on the severity of hypercalciuria. Third, some patients with IHP might have autoantibodies to the CaR (31) . If their antibodies function to activate the CaR, the pathophysiology of hypoparathyroidism in these patients may mimic gain-of-function mutations in the CaR.
The present study, a retrospective analysis of heterogeneous data sources, has methodological limitations. Urinary calcium data of different populations or different decades may preclude accurate comparison. However, except for those with CaR mutations reported previously (7), the subjects including normocalcemic controls are a current Japanese population and therefore are devoid of major differences in race, life style and diet. The collected data of patients with IHP are sufficient in number and the pretreatment serum calcium concentrations were similar to those of 60 cases analyzed by Parfitt (24) . For the patients with CaR mutations, the sample size was small because we selected them according to age and availability of urinary Ca/Cr data. However, their mean and the range of pretreatment serum calcium concentrations were similar to those calculated using all the data of previously published cases. Thus, we think the patients studied here are representative of the two disorders, and most of our findings are valid.
